Denosumab biosimilar HLX14 versus EU-denosumab in postmenopausal women at high fracture risk: a randomized, double-blind, multicenter phase 3 trial
Osteoporosis International · 04.11.2026
DOI: 10.1007/s00198-026-08262-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Osteoporosis International, online erschienen am 04.11.2026. Verfasst von Li Xin und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. ferryclouds@163.com. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shanghai Henlius Biotech, Inc..
Abstract (Originalsprache)
Biosimilars can increase access to efficacious drugs. This randomized, double-blind phase 3 study demonstrated efficacy equivalence between HLX14 and EU-denosumab and comparable safety, pharmacokinetics, and immunogenicity in postmenopausal women with osteoporosis at high risk of fracture. The findings provided direct evidence for HLX14 as a potential denosumab biosimilar. HLX14 is a proposed biosimilar of denosumab. This randomized, double-blind, multicenter, parallel-controlled phase 3 study aimed to compare the equivalence between HLX14 and European Union-sourced denosumab (EU-denosumab). Elderly female subjects with osteoporosis at high risk of fracture were randomized to receive two doses of HLX14 or EU-denosumab. At Week 52, subjects receiving EU-denosumab were re-randomized 1:1 to continue with a third dose of EU-denosumab or switch to HLX14, while those receiving HLX14 continued with a third dose of the drug. The co-primary endpoints were the percent change from baseline in lumbar spine BMD (LS-BMD) at Week 52, and the area under the effect-time curve for percent change of serum type I collagen C-telopeptide from baseline to Week 26 (AUEC_0-26W). Initially, 514 subjects were enrolled (256 vs. 258) across 40 hospitals in China. An increase in LS-BMD was evident in both groups (6.10% vs. 5.90%) at Week 52. The adjusted mean difference was 0.23% (90% confidence interval [CI]: −0.36%, 0.83%; 95% CI: −0.48%, 0.95%), demonstrating efficacy equivalence as the 95% and 90% CIs fell within the pre-specified equivalence margins of −1.45% to 1.45%. Similarly, pharmacodynamic equivalence was shown with the 95% and 90% CIs for the geometric mean ratio of AUEC_0-26W (1.01, 90% CI: 0.99, 1.04; 95% CI: 0.98, 1.05) fully contained within the equivalence margins of 0.8 to 1.25. The results of all secondary efficacy endpoints also supported the equivalence between HLX14 and EU-denosumab. Safety profiles were comparable and remained similar even after the single switch of treatment. The findings from this phase 3 study support biosimilarity between HLX14 and denosumab. Trial registration This trial was registered at Clinicaltrials.gov (NCT05352516).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. ferryclouds@163.com.
- Department of Nuclear Medicine, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Department of Orthopedics, Zhejiang Provincial People's Hospital, Hangzhou, China.
- Department of Orthopedics, Tianjin First Central Hospital, Tianjin, China.
- Department of Endocrinology, The Third Xiangya Hospital of Central South University, Changsha, China.
- Department of Orthopedics, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Beijing, China.
Förderung
- Shanghai Henlius Biotech, Inc.
Zitieren
APA
Xin, L., Li, Z., Zhang, J., Xia, Q., Jin, P., Xue, Q., Zheng, X., Tang, X., Yuan, Z., Shen, L., Duan, P., Zhang, Y., Huo, Y., Wang, B., Cheng, Z., Cao, Y., Li, L., Zeng, Y., Lan, L., …, & Zhu, J. (2026). Denosumab biosimilar HLX14 versus EU-denosumab in postmenopausal women at high fracture risk: a randomized, double-blind, multicenter phase 3 trial. Osteoporosis International. https://doi.org/10.1007/s00198-026-08262-5
Vancouver
Xin L, Li Z, Zhang J, Xia Q, Jin P, Xue Q, et al. Denosumab biosimilar HLX14 versus EU-denosumab in postmenopausal women at high fracture risk: a randomized, double-blind, multicenter phase 3 trial. Osteoporosis International. 2026. doi:10.1007/s00198-026-08262-5
BibTeX
@article{Xin2026,
author = {Xin, Li and Li, Zhiyong and Zhang, Jun and Xia, Qun and Jin, Ping and Xue, Qingyun and Zheng, Xin and Tang, Xin and Yuan, Zhong and Shen, Lin and Duan, Peng and Zhang, Yawei and Huo, Yanan and Wang, Bingwu and Cheng, Zhifeng and Cao, Youliang and Li, Liping and Zeng, Yuhong and Lan, Lizhen and Lu, Yibing and Mao, Li and Zhang, Zhan and Chen, Cong and Wang, Qingyu and Yu, Haoyu and Li, Jing and Zhu, Jun},
title = {Denosumab biosimilar HLX14 versus EU-denosumab in postmenopausal women at high fracture risk: a randomized, double-blind, multicenter phase 3 trial},
journal = {Osteoporosis International},
year = {2026},
doi = {10.1007/s00198-026-08262-5}
}
EUVIMED